Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23571028 | 1.00 | ADRB2 (0.55) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL30430000 | 1.00 | ADRB2 (0.55) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL12061497 | 0.83 | KCNH2 (0.49) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL7468533 | 0.80 | ADRB2 (0.56) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL4298647 | 0.80 | ADRB2 (0.56) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL3489603 | 0.80 | AOC3 (0.61) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL3920493 | 0.80 | ADRB2 (0.56) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL3487656 | 0.80 | AOC3 (0.61) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL2839905 | 0.80 | AOC3 (0.61) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL30839517 | 0.80 | AOC3 (0.61) | ADRB2ADRB1AOC3HIF1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082133-A | Synthetic method of tulobuterol | 上海医药工业研究院 | 2023-05-09 | — | — | CN | claimed |
| CN-111205194-A | Preparation method of tulobuterol | 山东达因海洋生物制药股份有限公司 | 2020-05-29 | — | — | CN | claimed |
| CN-114317620-B | Biological preparation method of (R) -2- (2-chlorophenyl) oxirane | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| CN-112707829-B | Toxolol crystal form and preparation method thereof | 山东达因海洋生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116082133-A | Synthetic method of tulobuterol | 上海医药工业研究院 | 2023-05-09 | — | — | CN | disclosed |
| CN-114317620-A | Biological preparation method of (R) -2- (2-chlorphenyl) oxirane | 上海医药工业研究院 | 2022-04-12 | — | — | CN | disclosed |
| CN-112707829-A | Tulobuterol crystal form and preparation method thereof | 山东达因海洋生物制药股份有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-111205194-A | Preparation method of tulobuterol | 山东达因海洋生物制药股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2016016118-A1 | MICROBIOCIDAL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-0493617-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE (-)-2-HALO-1-(SUBSTITUTED PHENYL)ETHANOL | KANEGAFUCHI CHEMICAL IND (JP) | 1999-10-06 | — | — | EP | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
| US-5266485-A | Biosynthesis | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-11-30 | — | — | US | disclosed |
| EP-0493617-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE (-)-2-HALO-1-(SUBSTITUTED PHENYL)ETHANOL AND (-)-SUBSTITUTED STYRENE OXIDE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-07-08 | — | — | EP | disclosed |
| US-4117157-A | TREATMENT OF CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | ADRB2 2440/4885ADRB1 866/4885AOC3 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.